A therapeutic dose of zolpidem reduces thalamic GABA in healthy volunteers: a proton MRS study at 4 T.
Saved in:
| Title: | A therapeutic dose of zolpidem reduces thalamic GABA in healthy volunteers: a proton MRS study at 4 T. |
|---|---|
| Authors: | Licata, Stephanie, Jensen, J., Penetar, David, Prescot, Andrew, Lukas, Scott, Renshaw, Perry |
| Source: | Psychopharmacology. May2009, Vol. 203 Issue 4, p819-829. 11p. 1 Color Photograph, 1 Diagram, 1 Chart, 2 Graphs. |
| Subjects: | Neurochemistry, Hypnotics, Imidazopyridines, Zolpidem, Amino acid neurotransmitters, GABA |
| Abstract: | Zolpidem is a nonbenzodiazepine sedative/hypnotic that acts at GABAA receptors to influence inhibitory neurotransmission throughout the central nervous system. A great deal is known about the behavioral effects of this drug in humans and laboratory animals, but little is known about zolpidem’s specific effects on neurochemistry in vivo. We evaluated how acute administration of zolpidem affected levels of GABA, glutamate, glutamine, and other brain metabolites. Proton magnetic resonance spectroscopy (1H MRS) at 4 T was employed to measure the effects of zolpidem on brain chemistry in 19 healthy volunteers. Participants underwent scanning following acute oral administration of a therapeutic dose of zolpidem (10 mg) in a within-subject, single-blind, placebo-controlled, single-visit study. In addition to neurochemical measurements from single voxels within the anterior cingulate (ACC) and thalamus, a series of questionnaires were administered periodically throughout the experimental session to assess subjective mood states. Zolpidem reduced GABA levels in the thalamus, but not the ACC. There were no treatment effects with respect to other metabolite levels. Self-reported ratings of “dizzy,” “nauseous,” “confused,” and “bad effects” were increased relative to placebo, as were ratings on the sedation/intoxication (PCAG) and psychotomimetic/dysphoria (LSD) scales of the Addiction Research Center Inventory. Moreover, there was a significant correlation between the decrease in GABA and “dizzy.” Zolpidem engendered primarily dysphoric-like effects and the correlation between reduced thalamic GABA and “dizzy” may be a function of zolpidem’s interaction with α1GABAA receptors in the cerebellum, projecting through the vestibular system to the thalamus. [ABSTRACT FROM AUTHOR] |
| Copyright of Psychopharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 37226640 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A therapeutic dose of zolpidem reduces thalamic GABA in healthy volunteers: a proton MRS study at 4 T. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Licata%2C+Stephanie%22">Licata, Stephanie</searchLink><br /><searchLink fieldCode="AR" term="%22Jensen%2C+J%2E%22">Jensen, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Penetar%2C+David%22">Penetar, David</searchLink><br /><searchLink fieldCode="AR" term="%22Prescot%2C+Andrew%22">Prescot, Andrew</searchLink><br /><searchLink fieldCode="AR" term="%22Lukas%2C+Scott%22">Lukas, Scott</searchLink><br /><searchLink fieldCode="AR" term="%22Renshaw%2C+Perry%22">Renshaw, Perry</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Psychopharmacology%22">Psychopharmacology</searchLink>. May2009, Vol. 203 Issue 4, p819-829. 11p. 1 Color Photograph, 1 Diagram, 1 Chart, 2 Graphs. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Neurochemistry%22">Neurochemistry</searchLink><br /><searchLink fieldCode="DE" term="%22Hypnotics%22">Hypnotics</searchLink><br /><searchLink fieldCode="DE" term="%22Imidazopyridines%22">Imidazopyridines</searchLink><br /><searchLink fieldCode="DE" term="%22Zolpidem%22">Zolpidem</searchLink><br /><searchLink fieldCode="DE" term="%22Amino+acid+neurotransmitters%22">Amino acid neurotransmitters</searchLink><br /><searchLink fieldCode="DE" term="%22GABA%22">GABA</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Zolpidem is a nonbenzodiazepine sedative/hypnotic that acts at GABAA receptors to influence inhibitory neurotransmission throughout the central nervous system. A great deal is known about the behavioral effects of this drug in humans and laboratory animals, but little is known about zolpidem’s specific effects on neurochemistry in vivo. We evaluated how acute administration of zolpidem affected levels of GABA, glutamate, glutamine, and other brain metabolites. Proton magnetic resonance spectroscopy (1H MRS) at 4 T was employed to measure the effects of zolpidem on brain chemistry in 19 healthy volunteers. Participants underwent scanning following acute oral administration of a therapeutic dose of zolpidem (10 mg) in a within-subject, single-blind, placebo-controlled, single-visit study. In addition to neurochemical measurements from single voxels within the anterior cingulate (ACC) and thalamus, a series of questionnaires were administered periodically throughout the experimental session to assess subjective mood states. Zolpidem reduced GABA levels in the thalamus, but not the ACC. There were no treatment effects with respect to other metabolite levels. Self-reported ratings of “dizzy,” “nauseous,” “confused,” and “bad effects” were increased relative to placebo, as were ratings on the sedation/intoxication (PCAG) and psychotomimetic/dysphoria (LSD) scales of the Addiction Research Center Inventory. Moreover, there was a significant correlation between the decrease in GABA and “dizzy.” Zolpidem engendered primarily dysphoric-like effects and the correlation between reduced thalamic GABA and “dizzy” may be a function of zolpidem’s interaction with α1GABAA receptors in the cerebellum, projecting through the vestibular system to the thalamus. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Psychopharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=37226640 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00213-008-1431-1 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 11 StartPage: 819 Subjects: – SubjectFull: Neurochemistry Type: general – SubjectFull: Hypnotics Type: general – SubjectFull: Imidazopyridines Type: general – SubjectFull: Zolpidem Type: general – SubjectFull: Amino acid neurotransmitters Type: general – SubjectFull: GABA Type: general Titles: – TitleFull: A therapeutic dose of zolpidem reduces thalamic GABA in healthy volunteers: a proton MRS study at 4 T. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Licata, Stephanie – PersonEntity: Name: NameFull: Jensen, J. – PersonEntity: Name: NameFull: Penetar, David – PersonEntity: Name: NameFull: Prescot, Andrew – PersonEntity: Name: NameFull: Lukas, Scott – PersonEntity: Name: NameFull: Renshaw, Perry IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: May2009 Type: published Y: 2009 Identifiers: – Type: issn-print Value: 00333158 Numbering: – Type: volume Value: 203 – Type: issue Value: 4 Titles: – TitleFull: Psychopharmacology Type: main |
| ResultId | 1 |
